Expected Outcome

  

The project could have a major positive impact on the quality of life of patients with Alzheimer disease and related dementias. As no specific treatment is available to improve cognitive dysfunction due to aging, our efforts will lead to the identification of novel druggable pathways directly useful for patients thanks to our innovative strategy based on a human and/or primate positive selection signature. This genetic interactions-focused project can be a springboard to other projects on interactions between genes, epigenetics and environmental factors.

  

AgedBrainSYSBIO partners will generate novel resources for European ageing research scientific community: a novel open-access database, novel validated protein-protein interactions in human and drosophila, novel human and/or primate positive selection signatures, novel iPSCs from control and patients with age pathologies and novel mouse models for cognitive defects linked to age.

  

Reducing health costs. The total annual costs of care per person suffering from Alzheimer disease and other dementias is estimated at 64,426 Euros in European countries. AgedBrainSYSBIO results are expected to have rapid translation in drug discovery for diseases for which no effective treatment is yet available.

  

Benefits for the European Biotechnology industry. AgedBrainSYSBIO will increase the portfolio and provide access to new business opportunities to the four well-established SMEs implicated: new technologies developed in the project will provide new products and services to technology-based SMEs (QURETEC, GeneBridges and HYBRIGENICS) and new targets and ultimately new drugs will benefit to the drug discovery SME reMYND. This will have a direct impact on the economic development and employment in Europe.

  

  

From new targets validated in AgedBrainSYSBIO will emerge new diagnostic tools and new drug discovery programs that will directly benefit to ageing populations

  

  

 


Last update on 2017-07-22

AgedBrainSYSBIO has received funding from the European Union’s Seventh Framework Programme for research,
technological development and demonstration under grant agreement No 305299
european flag blueyellow standard